What's Happening?
Atossa Therapeutics is set to host a virtual key opinion leader event featuring Dr. Laura Esserman to discuss the development of (Z)-endoxifen, an investigational selective estrogen receptor modulator/degrader
(SERM/D) for ER-positive breast cancer. The event will focus on clinical and translational data supporting (Z)-endoxifen as a potential next-generation endocrine therapy. Dr. Esserman, a renowned breast cancer expert, will address recent study findings and the therapy's potential applications.
Why It's Important?
The development of (Z)-endoxifen represents a promising advancement in the treatment of ER-positive breast cancer, offering a potential new option for patients who may not respond to existing therapies. By hosting this event, Atossa aims to engage with the medical community and highlight the potential of (Z)-endoxifen to improve treatment outcomes. This initiative underscores the importance of collaboration and knowledge sharing in advancing cancer research and therapy development.
What's Next?
Following the event, Atossa will continue to advance the clinical development of (Z)-endoxifen, with plans to explore its use in various breast cancer settings. The company will also focus on securing regulatory approvals and expanding its intellectual property portfolio to support the therapy's commercialization. As the research progresses, Atossa may seek strategic partnerships to enhance the development and distribution of (Z)-endoxifen.
